Cargando…

Inactivating BTK mutations in large B‐cell lymphoma in a real‐world cohort: Strong correlation with BCL2 translocation

Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor‐treatment naïve patients. Here, we report the BTK mutation status in a real‐world cohort of patients with non‐Hodgkin lymph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schejbel, Lone, Breinholt, Marie Fredslund, Gang, Anne Ortved, Nielsen, Torsten Holm, Pedersen, Lars Møller, Høgdall, Estrid, Nørgaard, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421985/ https://www.ncbi.nlm.nih.gov/pubmed/36051027 http://dx.doi.org/10.1002/jha2.489

Ejemplares similares

P1148: MULTI-SITE PRE-THERAPEUTIC BIOPSIES REVEALS GENETIC HETEROGENEITY IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
por: Stampe Hersby, Ditte, et al.
Publicado: (2023)

Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers
por: Pedersen, Mette Ølgod, et al.
Publicado: (2017)

Test of the FlashFREEZE unit in tissue samples freezing for biobanking purposes
por: Biskup, Edyta, et al.
Publicado: (2022)

Sexual dysfunction is highly prevalent in male survivors of malignant lymphoma
por: Micas Pedersen, Signe, et al.
Publicado: (2023)

P1177: ROUTINE CLINICAL FOLLOW-UP FOR RELAPSE DETECTION IN PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FIRST-LINE TREATMENT – DOES NOT MEET THE AIMS. A RETROSPECTIVE DANISH MULTICENTER STUDY
por: Lassen, Therese, et al.
Publicado: (2023)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022)

Bone Involvement as a Primary Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study
por: Bhatti, Khazra, et al.
Publicado: (2022)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40
por: DAUGAARD, SØREN, et al.
Publicado: (2009)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors
por: Rasmussen, Maria, et al.
Publicado: (2023)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
por: Peroja, Pekka, et al.
Publicado: (2018)

Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
por: Thieme, Elana, et al.
Publicado: (2022)

Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study
por: Ørtoft, Gitte, et al.
Publicado: (2019)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
por: Akpa, Chidimma Agatha, et al.
Publicado: (2019)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
por: Wang, Haoran, et al.
Publicado: (2021)

Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma.
por: Pezzella, F., et al.
Publicado: (1992)

Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
por: Sisman, Yagmur, et al.
Publicado: (2022)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
por: Luo, Qiuyun, et al.
Publicado: (2020)

Rare double-hit with two translocations involving IGH both, with BCL2 and BCL3, in a monoclonal B-cell lymphoma/leukemia
por: Alpatov, Roman, et al.
Publicado: (2015)

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
por: Wang, Sicong, et al.
Publicado: (2023)

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma
por: Yuan, Hongwei, et al.
Publicado: (2022)

Variant Translocation of the BCL6 Gene to Immunoglobulin k Light Chain Gene in B‐Cell Lymphoma
por: Suzuki, Ken, et al.
Publicado: (1994)

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
por: Nielsen, Boye Schnack, et al.
Publicado: (2014)

bcl‐2 Translocation in Japanese B Cell Lyraphoma: Novel bcl‐2 Translocation with Immunoglobulin Heavy Chain Diversity Segment
por: Seto, Masao, et al.
Publicado: (1991)

Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors
por: Bose, Prithviraj, et al.
Publicado: (2021)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations
por: Visco, Carlo, et al.
Publicado: (2017)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma
por: Nambiar, Mridula, et al.
Publicado: (2011)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0lm81mcu6gqefjl7fi701dpfpj